Intellia Therapeutics Inc
NTLA12.260USD
+0.770+6.70%
Market hours （ET）Quotes delayed by 15 min
1.27BMarket Cap
LossP/E TTM
More Details of Intellia Therapeutics Inc Company
Intellia Therapeutics, Inc. is a clinical-stage genome editing company, which is focused on developing curative therapeutics using Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) technology. CRISPR/Cas9 is a technology for genome editing, the process of altering selected sequences of genomic deoxyribonucleic acid. It is focused on leveraging its modular platform to advance in vivo and ex vivo therapies for diseases with high unmet need. Its lead in vivo candidate, NTLA-2001, is for the treatment of transthyretin (ATTR) amyloidosis, as well as NTLA-2002 for the treatment of hereditary angioedema (HAE) are the first CRISPR/Cas9-based therapy candidates to be administered systemically, via intravenous (IV) infusion, for precision editing of a gene in a target tissue in humans. It is also developing ex vivo applications to address immuno-oncology and autoimmune diseases.
Company Info
Ticker SymbolNTLA
Company nameIntellia Therapeutics Inc
IPO dateMay 06, 2016
CEODr. John M. Leonard, M.D.
Number of employees403
Security typeOrdinary Share
Fiscal year-endMay 06
Address40 Erie St Ste 130
CityCAMBRIDGE
Stock exchangeNASDAQ Global Market Consolidated
CountryUnited States of America
Postal code02139-4254
Phone18572856200
Websitehttps://www.intelliatx.com/
Ticker SymbolNTLA
IPO dateMay 06, 2016
CEODr. John M. Leonard, M.D.
Company Executives
Name
Name/Position
Position
Shareholding
Change
Dr. John M. Leonard, M.D.
Dr. John M. Leonard, M.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
893.46K
+10.09%
Ms. Eliana Clark, Ph.D.
Ms. Eliana Clark, Ph.D.
Executive Vice President, Chief Technology Officer
Executive Vice President, Chief Technology Officer
92.38K
-1.09%
Dr. David Lebwohl, M.D.
Dr. David Lebwohl, M.D.
Executive Vice President, Chief Medical Officer
Executive Vice President, Chief Medical Officer
51.64K
+125.03%
Dr. Frederick E. (Fred) Cohen, M.D.
Dr. Frederick E. (Fred) Cohen, M.D.
Independent Director
Independent Director
49.72K
+19.18%
Dr. Georgia Keresty, Ph.D.
Dr. Georgia Keresty, Ph.D.
Independent Director
Independent Director
24.15K
+49.55%
Mr. Brian M. Goff
Mr. Brian M. Goff
Independent Director
Independent Director
23.41K
+51.92%
Mr. William J. (Bill) Chase
Mr. William J. (Bill) Chase
Independent Director
Independent Director
19.97K
+66.85%
Ms. Muna Bhanji
Ms. Muna Bhanji
Independent Director
Independent Director
18.80K
+74.05%
Dr. Jesse Goodman, M.D.
Dr. Jesse Goodman, M.D.
Independent Director
Independent Director
16.62K
-8.51%
Mr. Michael P. Dube
Mr. Michael P. Dube
Chief Accounting Officer, Vice President
Chief Accounting Officer, Vice President
4.52K
-35.64%
View more
Name
Name/Position
Position
Shareholding
Change
Dr. John M. Leonard, M.D.
Dr. John M. Leonard, M.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
893.46K
+10.09%
Ms. Eliana Clark, Ph.D.
Ms. Eliana Clark, Ph.D.
Executive Vice President, Chief Technology Officer
Executive Vice President, Chief Technology Officer
92.38K
-1.09%
Dr. David Lebwohl, M.D.
Dr. David Lebwohl, M.D.
Executive Vice President, Chief Medical Officer
Executive Vice President, Chief Medical Officer
51.64K
+125.03%
Dr. Frederick E. (Fred) Cohen, M.D.
Dr. Frederick E. (Fred) Cohen, M.D.
Independent Director
Independent Director
49.72K
+19.18%
Dr. Georgia Keresty, Ph.D.
Dr. Georgia Keresty, Ph.D.
Independent Director
Independent Director
24.15K
+49.55%
Mr. Brian M. Goff
Mr. Brian M. Goff
Independent Director
Independent Director
23.41K
+51.92%
Revenue Breakdown
FY2025Q1
FY2024
FY2023
FY2022
No Data
By RegionUSD
Name
Revenue
Proportion
United States
16.63M
0.00%
By Business
By Region
No Data
Shareholding Stats
Updated: Fri, Jul 18
Updated: Fri, Jul 18
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
ARK Investment Management LLC
12.57%
The Vanguard Group, Inc.
10.36%
BlackRock Institutional Trust Company, N.A.
8.12%
State Street Global Advisors (US)
4.35%
Two Sigma Investments, LP
3.84%
Other
60.76%
Shareholders
Shareholders
Proportion
ARK Investment Management LLC
12.57%
The Vanguard Group, Inc.
10.36%
BlackRock Institutional Trust Company, N.A.
8.12%
State Street Global Advisors (US)
4.35%
Two Sigma Investments, LP
3.84%
Other
60.76%
Shareholder Types
Shareholders
Proportion
Investment Advisor
50.59%
Investment Advisor/Hedge Fund
20.47%
Hedge Fund
14.23%
Research Firm
6.53%
Corporation
3.57%
Individual Investor
1.49%
Bank and Trust
0.78%
Pension Fund
0.32%
Private Equity
0.22%
Other
1.79%
Institutional Shareholding
Updated: Tue, Jul 1
Updated: Tue, Jul 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q2
699
101.80M
98.27%
-16.60M
2025Q1
734
106.27M
102.60%
-9.72M
2024Q4
721
99.85M
96.57%
-1.86M
2024Q3
722
94.22M
92.84%
-2.81M
2024Q2
726
90.26M
93.51%
-7.71M
2024Q1
739
91.00M
94.49%
-893.96K
2023Q4
792
85.05M
91.49%
-3.09M
2023Q3
802
83.74M
94.78%
-6.96M
2023Q2
821
81.86M
93.61%
-7.70M
2023Q1
811
82.36M
94.28%
-4.97M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
ARK Investment Management LLC
13.01M
12.56%
+474.63K
+3.79%
Mar 31, 2025
The Vanguard Group, Inc.
10.73M
10.36%
+561.98K
+5.53%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
8.41M
8.12%
-411.95K
-4.67%
Mar 31, 2025
State Street Global Advisors (US)
4.51M
4.35%
-695.44K
-13.36%
Mar 31, 2025
Two Sigma Investments, LP
3.98M
3.84%
+120.05K
+3.11%
Mar 31, 2025
Capital International Investors
3.78M
3.65%
+3.78M
--
Mar 31, 2025
Regeneron Pharmaceuticals Inc
3.70M
3.57%
--
--
Mar 31, 2025
Citadel Advisors LLC
2.76M
2.66%
+263.50K
+10.56%
Mar 31, 2025
Nikko Asset Management Co., Ltd.
2.83M
2.73%
-167.30K
-5.59%
Mar 31, 2025
Geode Capital Management, L.L.C.
2.48M
2.39%
+90.93K
+3.81%
Mar 31, 2025
View more
Related ETFs
Updated: Sat, Aug 2
Updated: Sat, Aug 2
Name
Proportion
ARK Genomic Revolution ETF
2.65%
WisdomTree BioRevolution Fund
2.48%
ARK Innovation ETF
1.25%
Global X Genomics & Biotechnology ETF
1.17%
Virtus LifeSci Biotech Clinical Trials ETF
1.01%
Tema Neuroscience and Mental Health ETF
0.54%
SPDR S&P Biotech ETF
0.31%
Tema Heart & Health ETF
0.23%
Direxion Daily S&P Biotech Bull 3X Shares
0.17%
Avantis US Small Cap Equity ETF
0.12%
View more
ARK Genomic Revolution ETF
Proportion2.65%
WisdomTree BioRevolution Fund
Proportion2.48%
ARK Innovation ETF
Proportion1.25%
Global X Genomics & Biotechnology ETF
Proportion1.17%
Virtus LifeSci Biotech Clinical Trials ETF
Proportion1.01%
Tema Neuroscience and Mental Health ETF
Proportion0.54%
SPDR S&P Biotech ETF
Proportion0.31%
Tema Heart & Health ETF
Proportion0.23%
Direxion Daily S&P Biotech Bull 3X Shares
Proportion0.17%
Avantis US Small Cap Equity ETF
Proportion0.12%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
